Stock listing
NASDAQ:IMRX Immuneering Corporation Stock
Home listing (NASDAQ) of Immuneering Corporation
Follow Immuneering Corporation into a list and get an email when it puts out news.
Share price · NASDAQ:IMRX
$3.38 USD -0.12 (-3.4%)
Close on Nov 20, 2026
- Day range
- $3.29 – $3.54 USDNov 20, 2026
- Volume
- 1.45M sharesNov 20, 2026
- Market cap
- $218.7M USDAt the close on Nov 20, 2026 · price × 64.70M shares outstanding
- 52-week range
- $3.29 – $8.48 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.02M USDMedian day 709,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IMRX · Home | $3.38 USD | -0.12 (-3.4%) | 1,453,421 | $3.38 | $3.541 | $3.289 | $3.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.38 | -0.12 | -3.4% | $3.38 | $3.541 | $3.289 | 1,453,421 | |
| $3.50 | +0.04 | +1.2% | $3.46 | $3.575 | $3.43 | 730,703 | |
| $3.46 | -0.06 | -1.7% | $3.58 | $3.63 | $3.315 | 1,247,741 | |
| $3.52 | -0.19 | -5.1% | $3.70 | $3.78 | $3.475 | 1,019,933 | |
| $3.71 | +0.04 | +1.1% | $3.71 | $3.746 | $3.545 | 847,339 | |
| $3.67 | -0.12 | -3.2% | $3.86 | $3.885 | $3.65 | 476,835 | |
| $3.79 | -0.06 | -1.6% | $3.89 | $3.95 | $3.79 | 455,755 | |
| $3.85 | +0.20 | +5.5% | $3.66 | $3.895 | $3.65 | 769,411 | |
| $3.65 | -0.03 | -0.8% | $3.69 | $3.725 | $3.54 | 849,101 | |
| $3.68 | +0.31 | +9.2% | $3.41 | $3.695 | $3.368 | 681,434 | |
| $3.37 | -0.39 | -10.4% | $3.74 | $3.74 | $3.35 | 761,851 | |
| $3.76 | +0.08 | +2.2% | $3.74 | $3.87 | $3.70 | 730,404 | |
| $3.68 | +0.19 | +5.4% | $3.52 | $3.76 | $3.52 | 877,867 | |
| $3.49 | -0.255 | -6.8% | $3.76 | $3.94 | $3.445 | 799,866 | |
| $3.745 | -0.275 | -6.8% | $4.01 | $4.07 | $3.72 | 1,138,655 | |
| $4.02 | +0.03 | +0.8% | $3.99 | $4.10 | $3.875 | 770,876 | |
| $3.99 | +0.16 | +4.2% | $3.80 | $4.155 | $3.79 | 1,442,484 | |
| $3.83 | +0.12 | +3.2% | $3.72 | $3.888 | $3.70 | 699,488 | |
| $3.71 | -0.02 | -0.5% | $3.73 | $3.775 | $3.66 | 579,759 | |
| $3.73 | -0.08 | -2.1% | $3.78 | $3.78 | $3.585 | 726,538 | |
| $3.81 | +0.07 | +1.9% | $3.72 | $3.835 | $3.70 | 527,134 | |
| $3.74 | +0.01 | +0.3% | $3.73 | $3.80 | $3.68 | 481,881 | |
| $3.73 | +0.07 | +1.9% | $3.70 | $3.841 | $3.67 | 926,844 | |
| $3.66 | +0.07 | +1.9% | $3.61 | $3.67 | $3.56 | 427,112 | |
| $3.59 | -0.05 | -1.4% | $3.65 | $3.68 | $3.575 | 747,900 | |
| $3.64 | +0.22 | +6.4% | $3.42 | $3.71 | $3.38 | 934,300 | |
| $3.42 | -0.14 | -3.9% | $3.51 | $3.598 | $3.41 | 803,700 | |
| $3.56 | -0.30 | -7.8% | $3.86 | $3.86 | $3.545 | 734,400 | |
| $3.86 | -0.08 | -2.0% | $3.94 | $3.945 | $3.814 | 529,700 | |
| $3.94 | +0.20 | +5.3% | $3.75 | $3.955 | $3.68 | 709,700 | |
| $3.74 | -0.12 | -3.1% | $3.83 | $3.83 | $3.60 | 1,922,000 | |
| $3.86 | +0.03 | +0.8% | $3.78 | $3.915 | $3.74 | 747,700 | |
| $3.83 | -0.21 | -5.2% | $4.06 | $4.09 | $3.81 | 898,400 | |
| $4.04 | -0.03 | -0.7% | $4.07 | $4.12 | $4.02 | 479,700 | |
| $4.07 | +0.04 | +1.0% | $4.10 | $4.145 | $4.02 | 588,800 | |
| $4.03 | -0.065 | -1.6% | $4.10 | $4.17 | $4.01 | 538,200 | |
| $4.095 | -0.035 | -0.8% | $4.16 | $4.23 | $4.09 | 596,800 | |
| $4.13 | -0.03 | -0.7% | $4.16 | $4.16 | $4.065 | 574,400 | |
| $4.16 | -0.11 | -2.6% | $4.25 | $4.25 | $4.125 | 597,900 | |
| $4.27 | -0.07 | -1.6% | $4.36 | $4.40 | $4.255 | 513,400 | |
| $4.34 | -0.04 | -0.9% | $4.36 | $4.38 | $4.20 | 589,600 | |
| $4.38 | -0.23 | -5.0% | $4.62 | $4.65 | $4.355 | 551,500 | |
| $4.61 | +0.17 | +3.8% | $4.50 | $4.665 | $4.45 | 590,400 | |
| $4.44 | -0.04 | -0.9% | $4.55 | $4.57 | $4.38 | 540,300 | |
| $4.48 | +0.02 | +0.4% | $4.46 | $4.52 | $4.415 | 1,077,900 | |
| $4.46 | +0.01 | +0.2% | $4.55 | $4.55 | $4.405 | 576,100 | |
| $4.45 | +0.01 | +0.2% | $4.45 | $4.505 | $4.398 | 899,800 | |
| $4.44 | +0.11 | +2.5% | $4.33 | $4.475 | $4.24 | 862,100 | |
| $4.33 | +0.06 | +1.4% | $4.28 | $4.435 | $4.26 | 493,800 | |
| $4.27 | -0.30 | -6.6% | $4.63 | $4.65 | $4.24 | 901,400 | |
| $4.57 | -0.04 | -0.9% | $4.53 | $4.685 | $4.47 | 624,000 | |
| $4.61 | -0.17 | -3.6% | $4.74 | $4.81 | $4.54 | 1,165,700 | |
| $4.78 | -0.04 | -0.8% | $4.82 | $4.885 | $4.685 | 1,043,900 | |
| $4.82 | -0.22 | -4.4% | $4.94 | $5.00 | $4.805 | 999,900 | |
| $5.04 | +0.02 | +0.4% | $5.085 | $5.105 | $4.93 | 424,400 | |
| $5.02 | +0.17 | +3.5% | $4.85 | $5.055 | $4.80 | 678,600 | |
| $4.85 | -0.14 | -2.8% | $4.90 | $4.985 | $4.84 | 435,000 | |
| $4.99 | 0.00 | 0.0% | $5.00 | $5.01 | $4.863 | 587,400 | |
| $4.99 | -0.22 | -4.2% | $5.21 | $5.214 | $4.935 | 793,700 | |
| $5.21 | +0.06 | +1.2% | $5.19 | $5.395 | $5.12 | 787,700 | |
| $5.15 | -0.08 | -1.5% | $5.23 | $5.23 | $5.109 | 460,000 | |
| $5.23 | +0.05 | +1.0% | $5.20 | $5.38 | $5.20 | 364,300 | |
| $5.18 | -0.12 | -2.3% | $5.31 | $5.35 | $5.125 | 400,571 | |
| $5.30 | +0.05 | +1.0% | $5.31 | $5.43 | $5.281 | 443,600 | |
| $5.25 | -0.08 | -1.5% | $5.25 | $5.37 | $5.20 | 473,200 |
- Ticker
- NASDAQ:IMRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 28 slides
Latest news
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
Nov 18, 2026
Closed $3.50 (+1.2%) on Nov 18, 2026
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
Nov 18, 2026
Closed $3.50 (+1.2%) on Nov 18, 2026
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
Nov 12, 2026
Closed $3.67 (-3.2%) on Nov 12, 2026
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
Nov 12, 2026
Closed $3.67 (-3.2%) on Nov 12, 2026
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
Nov 9, 2026
Closed $3.65 (-0.8%) on Nov 9, 2026
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
Nov 6, 2026
Closed $3.68 (+9.2%) on Nov 6, 2026
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 4, 2026
Closed $3.37 (-10.4%) on Nov 5, 2026
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
Nov 4, 2026
Closed $3.76 (+2.2%) on Nov 4, 2026
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
Oct 29, 2026
Closed $3.75 (-6.8%) on Oct 30, 2026
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Oct 26, 2026
Closed $3.71 (-0.5%) on Oct 26, 2026
Immuneering Corporation on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 36 in the last 12 months · 107 in all · newest Nov 18, 2026 · oldest 2021
- Calls
- 2 calls with a replay · 2 with a transcript · latest Nov 12, 2025
- Decks
- 5 decks · latest September 2026
Where Immuneering Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IMRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IMRX | BOATS | United States | USD |
Valuation
Price/book 1.3× against a median of 1.6×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $160.5M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.17
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Immuneering Corporation · NASDAQ:IMRX | US$218.7M | US$160.5M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.17 |
| Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA | US$222.2M | US$82.43M | n/a | 1.3× | n/a | 2.8× | −108.3% | 0.7× | 1.11 |
| Clover Biopharmaceuticals Ltd. · HKEX:2197 | US$222.0M | US$206.5M | n/a | 403× | n/a | n/a | n/a | n/a | n/a |
| Aprilbio Co., Ltd. · KRX:397030 | US$221.1M | US$161.1M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | n/a |
| Northwest Biotherapeutics, Inc. · OTC:NWBO | US$220.0M | US$283.8M | n/a | 99.4× | n/a | n/a | n/a | n/a | 0.90 |
| Keros Therapeutics, Inc. · NASDAQ:KROS | US$219.7M | −US$24.67M | n/a | −0.6× | n/a | 0.8× | −152.7% | 0.1× | 1.16 |
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Median of the others | US$218.6M | US$121.7M | 50.3× | 1.6× | −130.5% | 0.1× | 1.16 |
Forecasts
5 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.26 · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ben Zeskind | Co-Founder, President, Chief Executive Officer, Director |
| Andrew Gengos | Chief Financial Officer and Treasurer |
| Dominic Capasso | Associate General Counsel |
| Michael Bookman | Chief Legal Officer, Secretary |
| David Caouette | Vice President, Corporate Communications |
| Jason Funt | Vice President, Translational Genomics |
| Kevin D. Fowler | Vice President, Translational Research |
| Loretta Sullivan | Vice President, Medical Affairs and Scientific Development |
| Mallory Morales | SVP Finance, Chief Accounting Officer, and Assistant Treasurer |
| Nair Praveen | Vice President, Head of Translational Pharmacology |
| Vinny Hayreh | Vice President, Clinical Development |
| Anna Travesa | Executive Director, Discovery |
| Bob Carpenter | Co-founder, Chair Emeritus |
| Brett Hall | Chief Scientific Officer |
| Doris Perez Diaz | Clinical Trial Manager |
| Igor Matushansky | Chief Medical Officer |
| Marty Hughes | Executive Director, CMC |
| Paula George | Senior Director, Accounting & Operations; Assistant Corporate Controller |
| Scott Nguyen | Executive Director, IT |
| Stephen Sebastian | Executive Director, Corporate Controller |
| Tyler Mead | Senior Manager, Financial Reporting and Internal Controls |
| Zhang Jenny | Executive Director, Genomic Data Science |
Board
| Director | Role |
|---|---|
| Bob Carpenter | Co-founder, Chair Emeritus |
| Tom Schall | Board Chair |
| Anna Travesa | Executive Director, Discovery |
| Ben Zeskind | Co-Founder, President, Chief Executive Officer, Director |
| Diana Hausman | Board Member |
| Grant Bogle | Board Member |
| Laurie Keating | Board Member |
| Marty Hughes | Executive Director, CMC |
| Peter Feinberg | Board Member |
| Scott Nguyen | Executive Director, IT |
| Stephen Sebastian | Executive Director, Corporate Controller |
| Zhang Jenny | Executive Director, Genomic Data Science |
Events
Calls
| Call | When | Status |
|---|---|---|
| Immuneering (NASDAQ:IMRX) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 4:30 PM ET | Replay |
| Immuneering (NASDAQ:IMRX) Q4 2022 Earnings Call | Mon, Mar 06, 2023 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | −6.8% |
| Q2 2026 | Aug 5, 2026 · Before open | −0.2% |
| Q1 2026 | May 12, 2026 | +3.5% |
| Q4 2025 | Mar 6, 2026 · Before open | +7.0% |
| Q3 2025 | Nov 12, 2025 · After close | −2.6% |
| Q2 2025 | Aug 13, 2025 · After close | −5.6% |
| Q1 2025 | May 5, 2025 · After close | −4.8% |
| Q4 2024 | Mar 20, 2025 | +7.1% |
| Q3 2024 | Nov 13, 2024 · After close | +13.4% |
| Q2 2024 | Aug 6, 2024 · After close | −8.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | +4.5% |
| Q4 2023 | Mar 1, 2024 · Before open | −0.8% |
| Q3 2023 | Nov 9, 2023 · After close | −0.3% |
| Q2 2023 | Aug 3, 2023 · After close | +1.9% |
| Q1 2023 | May 4, 2023 · After close | −0.6% |
| Q4 2022 | Mar 6, 2023 · After close | +6.2% |
| Q3 2022 | Nov 10, 2022 · Before open | 0.0% |
| Q2 2022 | Aug 10, 2022 · After close | −5.0% |
| Q1 2022 | May 10, 2022 · Before open | +14.0% |
| Q4 2021 | Mar 10, 2022 · Before open | −0.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 28 slides | September 2026 |
| Investor Presentation (November 2025) | Investor deck | 30 slides | November 2025 |
| Investor Presentation (September 2025) | Investor deck | 27 slides | September 2025 |
| Investor Presentation (April 2023) | Investor deck | 47 slides | Apr 18, 2023 |
| Investor Presentation (March 2023) | Investor deck | 39 slides | Mar 6, 2023 |
Financings
| Raise | Date |
|---|---|
| Public offering of class A common stock or pre-funded warrants Announced: Leerink Partners +1 Dealers: Leerink Partners (co-lead), Oppenheimer & Co. Inc. (co-lead) Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes | Sep 24, 2025 |
| Private placement of class A common stock or non-voting Class B common stock Announced: US$25M · Leerink Partners +1 Dealers: Leerink Partners, Oppenheimer & Co. Inc. Buyers: Sanofi ($25.0 million of Class A common stock or non-voting Class B common stock) Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes | Sep 24, 2025 |
| Private placement of class A common stock (or pre-funded warrants) and accompanying purchase warrants Closed: US$25M raised · US$3.95 a share · Warrants at US$5.5 for 60 months · Leerink Partners Dealers: Leerink Partners Use of proceeds: Support development of atebimetinib, its Deep Cyclic Inhibitor of MEK, for cancer patients | Aug 26, 2025 |
| At-the-market programme of common stock Closed: US$13.7M raised | Jan 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Jul 29, 2021.
- Price
- US$15.00 a share
- Shares offered
- 7,500,000 shares of Class A common stock
- Offering size
- US$112.5 million
- Underwriters' option
- Up to 1,125,000 more shares
- Listing
- IMRX on the Nasdaq Global Market
- Underwriters
- MORGAN STANLEY, JEFFERIES, COWEN, GUGGENHEIM SECURITIES · In the order on the cover
- Shares delivered
- On or about Aug 3, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 13, 2021 |
| Filed publicly | Jul 9, 2021 |
| Amended twice | Newest Jul 28, 2021 |
| Shares registered with an exchange | Jul 27, 2021 |
| Declared effective by the SEC | Jul 29, 2021 |
| Final prospectus, with the price | Jul 30, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 30, 2021 |
| EFFECT · Notice that a registration is effective | Jul 29, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jul 29, 2021 |
| CORRESP · Letter to the SEC | Jul 28, 2021 |
| S-1/A · Registration statement, amended | Jul 28, 2021 |
| UPLOAD · Letter from the SEC | Jul 27, 2021 |
| CERT · Exchange's certificate of listing | Jul 27, 2021 |
| CORRESP · Letter to the SEC | Jul 27, 2021 |
| CORRESP · Letter to the SEC | Jul 27, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 27, 2021 |
All 19 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jul 26, 2021 |
| CORRESP · Letter to the SEC | Jul 14, 2021 |
| CORRESP · Letter to the SEC | Jul 9, 2021 |
| S-1 · Registration statement | Jul 9, 2021 |
| UPLOAD · Letter from the SEC | Jul 1, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 21, 2021 |
| DRS/A · Draft registration statement, amended | Jun 21, 2021 |
| UPLOAD · Letter from the SEC | Jun 14, 2021 |
| DRS · Draft registration statement | May 13, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 317.0K | 2.08M | 2.31M | ||
| Cost of revenue | 0 | 158.1K | 1.15M | 1.28M | ||
| Gross profit | 0 | 158.8K | 926.9K | 1.03M | ||
| Research and development | 42.0M | 48.0M | 41.6M | 36.3M | 26.5M | 15.0M |
| Operating income | -59.4M | -64.1M | -58.4M | -51.7M | -33.9M | -17.1M |
| Depreciation and amortization | 324.5K | 355.8K | 322.8K | 247.2K | 45.5K | 24.3K |
| EBITDA | -59.1M | -63.7M | -58.1M | -51.5M | -33.8M | -17.1M |
| Income before tax | -50.5M | -33.8M | -17.0M | |||
| Income tax | 0 | -307.5K | ||||
| Net income | -56.0M | -61.0M | -53.5M | -50.5M | -33.5M | -17.0M |
| Earnings per share, basic | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 | -3.44 |
| Earnings per share, diluted | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 | -3.44 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 128.6M | 36.1M | 59.4M | 72.6M | 74.9M | 37.1M |
| Short-term investments | 0 | 26.3M | 32.9M | 74.3M | ||
| Receivables | 0 | 12.4K | 246.0K | 500.1K | ||
| Current assets | 176.2M | 39.6M | 89.1M | 108.7M | 152.3M | 37.7M |
| Property, plant and equipment | 938.5K | 1.12M | 1.40M | 1.37M | 807.2K | 64.4K |
| Goodwill | 6.69M | 6.69M | 6.69M | 6.69M | 6.70M | |
| Total assets | 232.0M | 52.7M | 102.6M | 122.4M | 166.7M | 38.4M |
| Accounts payable | 1.54M | 1.96M | 2.11M | 3.15M | 1.39M | 1.48M |
| Current liabilities | 10.1M | 7.50M | 7.85M | 8.05M | 5.63M | 2.26M |
| Total liabilities | 13.5M | 11.3M | 12.0M | 12.5M | 10.7M | 2.80M |
| Shareholders' equity | 218.5M | 41.4M | 90.6M | 109.9M | 156.0M | -22.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -45.3M | -55.0M | -49.0M | -44.1M | -30.9M | -14.6M |
| Capital spending | -142.2K | -84.9K | -342.7K | -742.5K | -60.8K | -53.4K |
| Free cash flow | -45.5M | -55.1M | -49.3M | -44.8M | -30.9M | -14.7M |
| Cash from investing | -88.7M | 26.4M | 7.30M | 41.8M | -75.6M | -53.4K |
| Cash from financing | 226.6M | 5.30M | 28.4M | 19.0K | 144.3M | 38.0M |
| Change in cash | 92.5M | -23.3M | -13.2M | -2.25M | 37.8M | 23.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 9, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 6, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 21, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Sep 25, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 25, 2025 | Material contract | SEC |
| FWP · Free writing prospectus | Sep 25, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Sep 24, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 24, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 24, 2025 | Material contract | SEC |
| 144 · Notice of proposed sale | Sep 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| D | Sep 9, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 8, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 4, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 2, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 22, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Aug 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 18, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 23, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | May 5, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 24, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K/A · Current report, amended | Oct 2, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 12, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 8-K · Current report | May 23, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 15, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 5, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 27, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 14, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 12, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 1, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 1, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 2, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 26, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Results | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | May 5, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 4, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | May 1, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 1, 2023 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 24, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 24, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 19, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Apr 19, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Apr 18, 2023 | Offer document | SEC |
This page holds 200 of 326 filings. Open Filings
Cap table
Built by 6ix from Immuneering Corporation’s releases · as of Sep 24, 2025
- Common shares
- 64,697,402
- Fully diluted
- 64,697,402
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 64,697,402 |
Warrants and options
| Lot |
|---|
| Warrants · US$5.50 · expire about Aug 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 64,697,402 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andrew Gengos Other companies: Turn Therapeutics Inc. (Director · Since at least Oct 7, 2025); Terns Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Feb 24, 2025); LeonaBio, Inc. (CFO and Chief Business Officer · May 18, 2023 – Sep 3, 2024 · Past); Cyteir Therapeutics Inc (Chief Business Officer · Jun 17, 2021 – Feb 22, 2022 · Past); Synlogic Inc (Chief Operating Officer · Oct 9, 2017 – Mar 14, 2018 · Past) | Chief Financial Officer and Treasurer · Since at least Jul 16, 2026 |
| Laurie Keating Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Jul 6, 2026); PepGen Inc. (Director · Since at least May 5, 2022); Imago Biosciences Inc (Director · Nov 17, 2021 – Jan 11, 2023 · Past); Alnylam Pharmaceuticals, Inc. (EVP, Chief Legal Officer · Jan 11, 2021 – Aug 5, 2021 · Past) | Director · Since at least Jul 29, 2021 |
| Ann E Berman Other companies: Loews Corporation (Director · Since at least Mar 1, 2021); Cantel Medical Corp (Director · Apr 5, 2021 – Jun 2, 2021 · Past); Eaton Vance Corp (Director · Nov 1, 2020 – Feb 12, 2021 · Past) | Director · Since at least Jul 29, 2021 |
| Diana Hausman Other companies: Zentalis Pharmaceuticals, Inc. (Chief Medical Officer · May 8, 2023 – May 9, 2024 · Past); Zymeworks Inc. (Chief Medical Officer · Jan 1, 2019 – Mar 10, 2021 · Past); Cascadian Therapeutics Inc (Chief Medical Officer · Mar 5, 2012 – Sep 24, 2015 · Past) | Board Member · Since at least Jan 14, 2022 |
| Biren Amin Other companies: Social Capital Suvretta Holdings Corp IV (Director · Jun 29, 2022 – Jun 29, 2022 · Past) | CFO, TREASURER · Jul 29, 2021 – May 12, 2022 · Past |
| Igor Matushansky Other companies: Hookipa Pharma Inc (Chief Medical Officer · Apr 17, 2019 – Jun 30, 2022 · Past) | Chief Medical Officer · Since at least Mar 17, 2025 |
| Michael Bookman Other companies: Korro Bio, Inc. (General Counsel and Secretary · Jan 19, 2021 – Apr 20, 2021 · Past) | Chief Legal Officer, Secretary · Since at least Jul 29, 2021 |
| Thomas J Schall Other companies: ChemoCentryx Inc. (President and CEO, Director · Feb 8, 2012 – Oct 20, 2022 · Past) | Director · Since at least Mar 11, 2024 |
| Amy Axel | Director, Scientific Operations · Oct 2, 2026 – Nov 10, 2026 · Past |
| Anna Travesa | Executive Director, Discovery · Since at least Nov 4, 2026 |
All 38 people
| Person | Seat |
|---|---|
| Benjamin J Zeskind | PRESIDENT AND CEO, Director · Since at least Jul 29, 2021 |
| Ben Zeskind | Co-Founder, President, Chief Executive Officer, Director · Since at least Jun 24, 2026 |
| Bob Carpenter | Co-founder, Chair Emeritus · Since at least Nov 10, 2026 |
| Brett Hall | Chief Scientific Officer · Since at least Jun 20, 2025 |
| David Caouette | Vice President, Corporate Communications · Since at least Oct 29, 2026 |
| Dominic Capasso | Associate General Counsel · Since at least Nov 10, 2026 |
| Doris Perez Diaz | Clinical Trial Manager · Since at least Nov 10, 2026 |
| Grant Bogle | Board Member · Since Nov 9, 2026 |
| Harold Eugene Brakewood | Chief Business Officer · Since at least Mar 27, 2023 |
| Jason Funt | Vice President, Translational Genomics · Since at least May 21, 2026 |
| Kevin D. Fowler | Vice President, Translational Research · Since at least Nov 5, 2026 |
| Leah Neufeld | CHIEF PEOPLE OFFICER · Since at least Oct 17, 2022 |
| Loretta Sullivan | Vice President, Medical Affairs and Scientific Development · Since at least Nov 10, 2026 |
| Mallory Morales | SVP Finance, CAO · Since at least Aug 11, 2022 |
| Marty Hughes | Executive Director, CMC · Since at least Nov 10, 2026 |
| Nair Praveen | Vice President, Head of Translational Pharmacology · Since at least Nov 10, 2026 |
| Paula George | Senior Director, Accounting & Operations; Assistant Corporate Controller · Since at least Nov 10, 2026 |
| Peter Feinberg | Board Member · Since at least Jul 29, 2021 |
| Praveen Nair | Vice President, Head of Translational Pharmacology · Nov 4, 2026 – Nov 10, 2026 · Past |
| Robert J Carpenter | Director · Since at least Jun 13, 2025 |
| Scott Barrett | CHIEF MEDICAL OFFICER · Jul 29, 2021 – Feb 15, 2023 · Past |
| Scott Nguyen | Executive Director, IT · Since at least Nov 10, 2026 |
| Stephen Sebastian | Executive Director, Corporate Controller · Since at least Nov 10, 2026 |
| Tom Schall | Board Chair · Since at least Nov 10, 2026 |
| Tyler Mead | Senior Manager, Financial Reporting and Internal Controls · Since at least Nov 10, 2026 |
| Vinny Hayreh | Vice President, Clinical Development · Since at least May 21, 2026 |
| Will Drew | Director, High Performance Computing · Nov 4, 2026 – Nov 10, 2026 · Past |
| Zhang Jenny | Executive Director, Genomic Data Science · Since at least Nov 10, 2026 |
Log in to ask 6ix AI your own questions about Immuneering Corporation.